Pfizer Inc. (NYSE:PFE) Stock Position Cut by Blackhill Capital Inc.

Blackhill Capital Inc. reduced its stake in Pfizer Inc. (NYSE:PFE) by 3.8% in the fourth quarter, HoldingsChannel reports. The fund owned 51,146 shares of the biopharmaceutical company’s stock after selling 2,000 shares during the quarter. Pfizer makes up 0.1% of Blackhill Capital Inc.’s holdings, making the stock its 25th largest holding. Blackhill Capital Inc.’s holdings in Pfizer were worth $1,357,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in the stock. WealthTrust Axiom LLC lifted its holdings in shares of Pfizer by 10.7% in the fourth quarter. WealthTrust Axiom LLC now owns 197,648 shares of the biopharmaceutical company’s stock valued at $5,244,000 after buying an additional 19,035 shares during the period. Sagespring Wealth Partners LLC bought a new position in shares of Pfizer during the 4th quarter valued at about $1,117,000. Rockefeller Capital Management L.P. grew its stake in shares of Pfizer by 2.2% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,665,404 shares of the biopharmaceutical company’s stock worth $44,189,000 after purchasing an additional 35,315 shares during the last quarter. NFP Retirement Inc. lifted its stake in Pfizer by 8.4% during the fourth quarter. NFP Retirement Inc. now owns 7,920 shares of the biopharmaceutical company’s stock valued at $210,000 after purchasing an additional 614 shares during the last quarter. Finally, Inlight Wealth Management LLC acquired a new position in Pfizer in the fourth quarter worth approximately $3,236,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Insiders Place Their Bets

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of Pfizer stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.06% of the company’s stock.

Pfizer Price Performance

PFE opened at $21.89 on Friday. The stock has a fifty day moving average price of $25.25 and a 200 day moving average price of $26.40. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The stock has a market cap of $124.14 billion, a price-to-earnings ratio of 15.52, a PEG ratio of 0.64 and a beta of 0.67.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. During the same quarter in the previous year, the business posted $0.10 EPS. The firm’s quarterly revenue was up 24.7% compared to the same quarter last year. Analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on PFE. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. The Goldman Sachs Group reissued a “neutral” rating and issued a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research note on Monday, March 10th. Citigroup restated a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. Finally, UBS Group lowered their price objective on shares of Pfizer from $28.00 to $24.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $31.07.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.